anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Female infertility constitutes a growing health problem in developing countries and could be associated with several possible causes including reproductive disorders, congenital malformations, infections and hormonal dysfunction. Nonetheless, a series of additional factors can also negatively impact female fertility and are represented by chronic exposure to environmental pollutants, stress, unhealthy lifestyle choices such as cigarette smoking and, among others, obesity. Excess weight is associated with several chronic diseases, and growing evidence demonstrates that it can compromise reproductive physiology due to its influence on endometrial gene expression and receptivity. Thus, the current review of the literature mainly focused on how obesity can impair uterine receptivity, mostly from a molecular point of view throughout the window of implantation (WOI) period at an endometrial level. It was also highlighted that an obesity-related increase in adipose tissue may lead to a modulation in the expression of multiple pathways, which could cause a hostile endometrial environment with a consequent negative impact on the uterine receptivity and the establishment of pregnancy. Thanks to the use of the endometrial receptivity assay (ERA), a specific microarray that studies the expression of a series of genes, it is now possible to evaluate the endometrial status of patients with infertility problems in a more detailed manner. Moreover, female fertility and endometrial receptivity could be affected by endometriosis, a chronic benign gynecological disease, whose cause-and-effect relationship to obesity is still uncertain. Therefore, further investigations would be required to better elucidate these mechanisms that govern embryo implantation and could be potentially useful for the generation of new strategies to overcome implantation failure and improve the pregnancy rates in obese women.
The application relates to the technical field of machine learning and deep learning, and provides a multi-label arrhythmia distinguishing method based on a multi-scale neural network model. The method comprises the following steps: preprocessing the original electrocardiogram data, and extracting key characteristics of arrhythmia, including time domain, frequency domain and time-frequency characteristics. And constructing a multi-branch network model, wherein each branch is used for learning arrhythmia characteristics corresponding to different frequency ranges. Secondly, training the model by using the marked arrhythmia data to form a multi-label arrhythmia distinguishing model. Finally, classification and prediction are performed through the trained model using real-time acquired electrocardiographic data, and feedback regulation results are generated to optimize the model or provide a reference to a doctor. Therefore, the method and the device achieve multi-scale analysis and processing of arrhythmia signals by utilizing a multi-scale neural network model, ensure that nonlinearity and complexity of arrhythmia signals can be better processed, and improve classification precision and prediction accuracy.
A cosmetic agent is disclosed comprising a cosmetically useful group bound to an amino functional group by a linking moiety. The linking moiety comprises an alkylidene or an arylidene group bearing two carboxyl groups. The cosmetically useful group is bound to one carboxyl group of the linking moiety, while the amino functional group is bound to the other carboxyl group of the linking moiety. The amino functional group comprises an amino substituent bound to a carbon atom of an alkylidene group having an oxygen substituent, and the oxygen substituent is bound to the other carboxyl group of the linking moiety by an ester bond. The amino substituent can be a primary amino substituent, a secondary amino substituent, a tertiary amino substituent, or a quaternary amino substituent. Preferably the amino substituent is a tertiary or a quaternary amino substituent. Methods for preparing, and compositions comprising, cosmetic agents of this invention are also disclosed.
Polymorphic light eruption (PLE) has been mechanistically linked to cytokine abnormalities. Emerging preclinical evidence posits the skin microbiome as a critical modulator of ultraviolet (UV)-induced cytokine expression, thereby influencing subsequent immune responses. This intricate relationship remains underexplored in the context of PLE. Hence, we investigated the differential responses between disinfected and non-disinfected skin following both single and repetitive exposures to solar-simulated UV radiation in patients with PLE. An experimental, half-body pilot study was conducted involving six PLE patients and 15 healthy controls. Participants' skin was exposed to single and multiple doses of solar-simulated UV radiation, both in disinfected and in non-disinfected skin areas. The co-primary outcomes were PLE score and cytokine expression in blister fluid analysed through OLINK proteomic profiling. Secondary outcomes were erythema, pigmentation, induction of apoptotic cells in vacuum-generated suction blisters, and density of infiltrate in skin biopsies of PLE patients. Among the 71 cytokines analysed, baseline expression levels of 20 specific cytokines-integral to processes such as apoptosis, inflammation, immune cell recruitment, cellular growth, and differentiation-were significantly impaired in PLE patients compared with healthy controls. Notably, skin disinfection reversed the observed cytokine imbalances following a single UV exposure at the minimal erythema dose (MED) level and exhibited even more pronounced effects after multiple UV exposures. However, no significant differences were evident in PLE score, erythema, pigmentation, or rates of apoptotic cell induction upon UV radiation. These findings provide evidence for UV-driven cytokine regulation by the skin microbiota and imply microbiome involvement in the PLE immune response.
PURPOSE: A hair conditioning composition is provided to ensure glossiness, smoothness, and freshness. CONSTITUTION: A hair conditioning composition contains 50-90wt% of volatile silicon oil and 10-50wt% of non-volatile silicon oil. The viscosity of the volatile silicon oil is 0.5-5cs. The volatile silicon oil is straight chain polysiloxane oil or cyclic polysiloxane oil with a viscosity of 0.5-5cs. The viscosity of the non-volatile silicon oil is 1,000-5,000cs. The non-volatile silicon oil is selected from the group consisting of polydimethylsiloxane, phenylsiloxane, alkyl methyl siloxane, dimethicone, cyclomethicone, dimethiconol, a dimethicon copolymer, silicon elastomer, and a silicon resin. The non-volatile silicon oil and the volatile silicon oil are mixed in a ratio of 1:1 to 1:30.
Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy. 

The VA NEPHRON trial enrolled 1448 patients with type 2 diabetes, elevated urinary-albumin-to-creatinine ratio, and decreased estimated glomerular filtration rate (GFR 30 to 89.9 ml/min), randomized them to lisinopril or placebo on a background of losartan therapy and followed them for a median of 2.2 years. Patients receiving the combination of losartan and lisinopril did not obtain any additional benefit compared to monotherapy for the combined endpoint of decline in GFR, end state renal disease, or death, but experienced an increased incidence of hyperkalemia and acute kidney injury compared with the monotherapy group.

In general, avoid combined use of RAS inhibitors, closely monitor blood pressure, renal function and electrolytes in patients on Lisinopril and Hydrochlorothiazide Tablets and other agents that affect the RAS. 

Do not co-administer aliskiren with Lisinopril and Hydrochlorothiazide Tablets in patients with diabetes. Avoid use of aliskiren with Lisinopril and Hydrochlorothiazide Tablets in patients with renal impairment (GFR < 60 ml/min).

Other Agents: Lisinopril has been used concomitantly with nitrates and/or digoxin without evidence of clinically significant adverse interactions. No meaningful clinically important pharmacokinetic interactions occurred when lisinopril was used concomitantly with propranolol, digoxin, or hydrochlorothiazide. The presence of food in the stomach does not alter the bioavailability of lisinopril.

Agents Increasing Serum Potassium: Lisinopril attenuates potassium loss caused by thiazide-type diuretics. Use of lisinopril with potassium-sparing diuretics (e.g., spironolactone, eplerenone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium. Therefore, if concomitant use of these agents is indicated, because of demonstrated hypokalemia, they should be used with caution and with frequent monitoring of serum potassium.

Lithium: Lithium toxicity has been reported in patients receiving lithium concomitantly with drugs which cause elimination of sodium, including ACE inhibitors. Lithium toxicity was usually reversible upon discontinuation of lithium and the ACE inhibitor. It is recommended that serum lithium levels be monitored frequently if lisinopril is administered concomitantly with lithium.

mTOR (mammalian target of rapamycin) inhibitors

Patients receiving coadministration of ACE inhibitor and mTOR inhibitor (e.g., temsirolimus, sirolimus, everolimus) therapy may be at increased risk for angioedema (see WARNINGS)
AIM: To review histologically confirmed diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH) cases and carry out a detailed pathological-radiological correlation to see if computed tomography (CT) can be used to confidently identify DIPNECH.
MATERIALS AND METHODS: Twenty-three histologically confirmed DIPNECH patients in the shared database of two NHS Trusts were reviewed. CT images were reviewed by two independent radiologists, each of them with >10 years of experience in thoracic imaging. All histological specimens were reviewed by a single pathologist with >25 years of experience. The diagnosis of DIPNECH was made according to the current World Health Organization (WHO) definition included in the WHO 2015 classification of pulmonary tumours. The results on histology were compared to the presence of nodules and air trapping on CT. Demographic information and, when available, molecular imaging studies and pulmonary function tests were also considered.
RESULTS: There are prototypal clinical and radiological findings reflecting the presence of underlying histological DIPNECH: middle-aged women with multiple small and scattered nodules due to the clustering and proliferation of neuroendocrine cells. At least one larger, dominant, lung nodule reflecting a carcinoid tumour is very common and mosaic attenuation/air trapping is seen approximately in 50% of cases in inspiratory scans. Airflow obstruction is rarely associated with histological bronchial or peribronchial fibrosis, which suggests other mechanisms must be involved in its development.
CONCLUSION: CT can be used to predict pathological DIPNECH in the appropriate clinical setting. It is important to consider DIPNECH to avoid overdiagnosis of more sinister conditions such as lung cancer or metastases.
The Late Total Caloric Intake study group will have scheduled meal times for the entire 6 day semi ambulatory and in lab session and will consume 40% of daily calories during breakfast and lunch. The remaining 60% of daily calories will be consumed during dinner. This is a model for late dietary chronotype.
A new topical pharmaceutical compsn. having enhanced penetration through the skin comprises (a) a safe and effective amt. of a pharmaceutical active; and (b) from 0.1-10.0% of a high molecular wt. crosslinked cationic polymer of the formula (A)l(B)m(C)n where the polymer contains a crosslinking agent, where (A) is dialkylaminoalkyl acrylate monomer or its quat. ammonium or acid addn. salt; (B) is a dialkylaminoalkyl methacrylate monomer or its quat. ammonium or acid addn. salt; (C) is acrylamide; l is an integer of 0 or greater; m is an integer of 1 or greater; n is an integer of 0 or greater.
This research is being done to see if it is safe and feasible to give the investigational drugs, nivolumab (also known as BMS-936558) before surgery to people with newly diagnosed or recurrent squamous cell carcinoma of head and neck (SCCHN). Patients with recurrent disease may have a limited number of sites of metastatic (spread) squamous cell carcinoma of head and neck. Another goal of this study is to learn how nivolumab impacts the immune system's ability to treat the cancer. While nivolumab is approved by the U. S. Food and Drug Administration (FDA) for the treatment of patients with metastatic SCCHN with progression on or after platinum-based chemotherapy, the word "investigational" in this context means that the study drugs are not approved by the FDA for the treatment of head and neck cancers prior to surgery and thus is still being tested in research studies. However, the FDA is allowing the use of nivolumab in this study.

This study will have two arms. Cohort (arm) 1 will examine one dose of nivolumab given about 4 weeks before surgical resection (removal) of a newly diagnosed SCCHN. Twelve patients will be enrolled to this arm. Cohort 2 will examine one dose of nivolumab given about 4 weeks before surgical resection (removal) of SCCHN which has recurred and possibly spread to distant sites, but still can be resected with one surgery. Twelve patients will be enrolled to this arm.
From a previous biopsy, articular cartilage matrix is digested and chondrocytes are cultured in 2 passages until implants with at least 6,000,000 cells are constructed. These constructus of 8 mm in diameter are implanted arthroscopically by means of biodegradable anchor (MINILOK QUICKANCHOR TM from DePuy-Mitek ) located at the defect and tied securely.
Cerebral Palsy (CP) is a group of permanent disorders in activity limitation, motor and posture development due to non-progressive damage to the developing fetus or infant brain. In spastic bilateral CP, involvement is seen bilaterally in all 4 extremities.
Patients received Fentanyl 0.3 mcg/Kg/h infused at 2 ml/h for 24 hours. The infusion contained morphine and saline.
1366031 Self-hardening compositions ESPE FABRIK PHARMAZEUTISCHER PRAPARATE GmbH 14 Jan 1972 [15 Jan 1971] 1784/72 Heading C3P A self-hardening composition suitable for use as a dental cement, comprises water, a polymer of an unsaturated α,#-dicarboxylic acid and surgically acceptable zinc oxide. In the examples the compositions comprise polymaleic acid, zinc oxide, magnesium oxide, water, bismuth phosphate, aluminium oxide, calcium fluoride and polyitaconic acid. Other suitable polymers are copolymers of maleic acid and itaconic acid, copolymers with unsaturated monocarboxylic acids, e.g. acrylic acid or methacrylic acid and copolymers with monomers free of carboxyl groups, e.g. methacrylates, acrylamide, methacrylamide and their nitrogen-substituted derivatives. A surgical cement-forming pack comprises in at least two separate compartments, the polymer, zinc oxide and water, no compartment containing more than two of these.
Ethyleneimine is used as an inactivating agent in the prodn. of antigens or imunogens for pharmaceutical prepns. It is easily produced on a technical scale, is very stable and easy to store, and in a first-order reaction gives rapid and certain inactivation of infectious microorganisms without affecting their antigenicity or immunogenicity. It is therefore partic. suitable for producing inactivated microbial antigenic or immunogenic prods. such as viral or bacterial vaccines.
PURPOSE: This study reports pilot data for a novel intervention, ECoLoGiC-Tx, delivered to four people with moderate to severe aphasia. ECoLoGiC-Tx addresses language and communication in unstructured, participant-led conversation. The speech-language pathologist (SLP) uses a framework to choose turns that facilitate a social interaction. When communication breakdown occurs, the SLP implements a least-to-most hierarchy to maximize the people with aphasia's (PWA's) independence in self-repair. ECoLoGiC-Tx draws its theoretical underpinnings from conversation analysis and theories of rehabilitation, including principles of complexity, neuroplasticity, and learning.
METHOD: Four PWA attended 60-min sessions twice weekly for 10 weeks. Assessment occurred at pretreatment, posttreatment, and 6-week maintenance. Outcomes included established discourse measures for conversation and monologue, tests of language and functional communication, and patient-/family-reported outcome measures (P/FROMs). Discourse samples were collected three times per assessment. Interrater reliability and fidelity for assessment and treatment procedures are reported.
RESULTS: Participants presented with Broca's aphasia (one moderate, one severe) or conduction aphasia (one moderate, one severe). Each demonstrated improvements in discourse, test batteries, and P/FROMs. They all demonstrated reduced aphasia severity measured by the Western Aphasia Battery-Revised at posttreatment or maintenance. Change in conversation and monologue was robust for three participants, but was mixed for one person (P1: moderate Broca's aphasia). P/FROMs indicated improvement at posttreatment and maintenance for all participants. Most treatment gains were maintained at 6-week follow-up.
CONCLUSIONS: This study provides promising results for ECoLoGiC-Tx to improve language function of people with chronic moderate to severe aphasia. Generalization occurred to tests, functional communication, spontaneous conversation, and structured monologue tasks.
PROBLEM TO BE SOLVED: To eliminate the need to reinput attribute information and to make operation efficient by adding an input function for classification data to the image filing system and storing a database with an image which is being displayed as an input object of classification data together with automatically retrieved attribute information. SOLUTION: A DSP 14 is a patient management system which is installed in a hospital and stored with patient numbers, patient names, blood groups, etc. Consequently, an identification number of blood to be inspected, e.g. a sample number is inputted from the side of the main body 1 of the blood cell image filing system and then the patient attribute and sample attribute corresponding to the sample number can be obtained from the DSP 14. Those pieces of attribute information can be obtained by selecting only specific items needed to file blood cell images on the side of the main body 1. Then image data on a blood cell inputted through a CCD camera 5 etc., are stored in the data base 3 together with the attribute information of the DSP 14.
Immunotherapy with HD-IL-2 has produced durable benefit in 10% of patients with metastatic cutaneous melanoma. The antitumor activity of IL-2 has been limited at least in part by immunosuppressive and immune-regulatory forces within the tumor microenvironment. Antibodies against CTLA4 (e.g. ipilimumab), PD1 and its ligand (PD-L1) produced long-term benefit in approximately 20-40% of patients with advanced melanoma. In addition, the combination of ipilimumab with the anti-PD1 antibody, nivolumab, has shown tumor responses in up to 60% of patients with advanced melanoma. These findings have led to FDA approval of ipilimumab and nivolumab as an indication for treatment of patients with advanced melanoma and nivolumab for other cancers. While these data are exciting, only a few patients enrolled to the prior studies had metastatic MCM or ALM. There is no prospective immunotherapy studies conducted in MCM or ALM-specific population. Therefore the activity of the ipilimumab + nivolumab combination in these subsets or patients remains unknown

Reliable predictive biomarkers for the use of immune checkpoint inhibitors are needed to identify pretreatment those patients most likely to respond and early on in treatment assays could help identify mechanisms of tumor response and resistance necessary to improve therapy. Although tumor PD-L1 expression in tumor confers higher treatment response rate, responses to nivolumab or nivolumab + ipilimumab alone were noted in 55% and 41% of patients, respectively, with PD-L1- tumors. Therefore, more reliable predictive biomarkers are needed.

Recently, extensive studies on metastatic colorectal cancer have demonstrated that a new scoring system as well as density of immune cells infiltrates at the center of the tumor and its invasive margin, described as Immunoscore, could accurately separate a group of patients with high Immunoscore with improved DFS, and OS from those with low Immunoscore where the histopathological staging system cannot. A recent study has also demonstrated relationship between degree of pre-treatment CD8+ tumor infiltrating lymphocytes (TILs) infiltration and PD-L1 expression at the invasive margin of the advanced cutaneous melanoma and improved long-term clinical benefits in patients with advanced melanoma who received pembrolizumab monotherapy. Further, there appeared to be an association between tumor response and clonality of the immune infiltrate based on a next-generation sequencing method used to evaluate T-cell receptor rearrangement pre- and in response to checkpoint inhibitor therapy. Also, high mutational burden correlated with overall survival in patients with cutaneous melanoma treated with ipilimumab or lung cancer treated with anti-PD1. However, the biology of MCM and ALM are distinct from cutaneous melanoma at multiple levels. Consequently, the utility of predictive biomarkers developed for cutaneous melanoma remains unknown.
PROBLEM TO BE SOLVED: To facilitate medication fee changing by retrieving a medication belonging to a group designated by inputted information, and changing the medication fee stored concerning the retrieved medication to an inputted medication fee. SOLUTION: A control part 13 instructs a retrieval part 11 to retrieve the designated first medication effect group in revise information in a memory 14. The retrieval part 11 accesses to an external storage device 23 and retrieves a stored medication data base 30 from the head. Then, a medication code having the designated medication effect group in its record, namely, the first discovered record among the records of medications included in the designated medication effect group is read out and returned to the control part 13. The control part 13 dispatches the received record and the new medication fee stored in the memory 14 to a register part 12 and instructs the change of the medication fee. After the medication fee in the record is changed with the new medication fee, the register part 12 writes the record back to the medication data base 30.
A total of 519 RA patients 65 years of age and older, including 107 patients 75 years of age and older, received adalimumab in clinical studies RA-I through IV. No overall difference in effectiveness was observed between these patients and younger patients. The frequency of serious infection and malignancy among adalimumab treated patients 65 years of age and older was higher than for those less than 65 years of age. Consider the benefits and risks of HADLIMA in patients 65 years of age and older. In patients treated with HADLIMA. closely monitor for the development of infection or malignancy [see Warnings and Precautions (5.1, 5.2)].